Orforglipron vs BPC-157
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
OrforglipronRecovery & Repair
BPC-157- Summary
- Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
- BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in the stomach. It is one of the most extensively researched healing peptides, known for accelerating tissue repair, reducing inflammation, and protecting the gastrointestinal tract.
- Half-Life
- ~12 hours (once-daily oral dosing)
- 4–6 hours
- Admin Route
- Oral
- SubQ, IM, Oral
- Research
- —
- —
- Typical Dose
- 12 mg → 24 mg → 36 mg → 45 mg
- 200–500 mcg
- Frequency
- Once daily
- Once daily
- Key Benefits
- Oral pill — no injections required
- Once-daily dosing without food restrictions (unlike oral semaglutide)
- Up to 9.4% body weight reduction in Phase 2 at 36 weeks
- Significant HbA1c reduction in type 2 diabetes trials
- Small-molecule stability — no cold chain requirements
- Broadens access for injection-averse patients
- Potential class-defining convenience advantage over injectable GLP-1s
- Accelerates wound healing and tissue repair
- Reduces inflammation throughout the body
- Protects and heals the gastrointestinal tract
- Supports tendon and ligament healing
- Promotes bone and joint health
- May protect organs from toxins and injury
- Supports gut-brain axis function
- Counteracts NSAID-induced gut damage
- Side Effects
- Nausea (most common, dose-dependent)
- Vomiting
- Diarrhea
- Decreased appetite
- +2 more
- Injection site discomfort
- Nausea (rare)
- Headache (rare)
- Dizziness (rare)
- Stacks With
- —
- —